Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 13:24:1511-1516.
doi: 10.12659/msm.907918.

Cytokine, C-Reactive Protein, and Heat Shock Protein mRNA Expression Levels in Patients with Active Behçet's Uveitis

Affiliations

Cytokine, C-Reactive Protein, and Heat Shock Protein mRNA Expression Levels in Patients with Active Behçet's Uveitis

Eda Balkan et al. Med Sci Monit. .

Abstract

BACKGROUND To investigate the gene expression levels of interleukin 10 (IL10), IL18, interferon gamma (IFNG), IFN-gamma receptor (IFNGR), C-reactive protein (CRP), and heat shock protein 70 (HSP70) in patients with active Behçet's uveitis. MATERIAL AND METHODS Forty patients with Behçet's disease diagnosed according to the International Study Group criteria and 30 healthy individuals were included in the study. IL10, IL18, IFNG, IFNGR, CRP, and HSP70 gene expression levels were compared. RESULTS Expression levels of IL18, IFNG, IFNGR, and CRP were significantly higher in patients with active Behçet's uveitis than in control subjects (P<0.01 for all), whereas no significant differences were found in IL10 and HSP70 gene expression levels (P>0.01 for both). CONCLUSIONS IL18, IFNG, IFNGR, and CRP gene expression is significantly increased in active Behçet's uveitis. There was no significant difference between active Behçet's uveitis patients and controls in terms of IL10 and HSP70 gene expression levels. We conclude that drugs prescribed to Behçet's patients with active uveitis downregulate gene expression.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Zierhut M, Mizuki N, Ohno S, et al. Immunology and functional genomics of Behcet’s disease. CellMol Life. 2003;60:1903–22. - PMC - PubMed
    1. Taheri S, Borlu M, Evereklioglu C, et al. mRNA expression level of interleukin genes in the determining phases of Behçet’s disease. Ann Dermatol. 2015;27:291–97. - PMC - PubMed
    1. Alpsoy E. Behçet disease: An update in etiopathogenesis. Turk J Dermatol. 2013;7:41–45.
    1. Gurler A, Boyvat A, Tursen U. Clinical manifestations of Behcet’s disease: An analysis of 2147 patients. Yonsei Med J. 1997;38:423–27. - PubMed
    1. Alpsoy E, Zouboulis CC, Ehrlich CE. Mucocutaneous lesions of Behcet’s disease. Yonsei Med J. 2007;48:573–85. - PMC - PubMed